SecBot SecBot
PREM14A ·Filed Aug 10, 2026

TECH

BIO-TECHNE Corp
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001140361-26-032037
Preliminary proxy statement (merger-related)
Actionable Insight ▲ Bullish

The deal offers a substantial cash premium with a high likelihood of closing given no financing condition and a clear regulatory path. The primary risk is regulatory delay or a 'Burdensome Condition' that could scuttle the deal. Monitor HSR and foreign antitrust approvals; the stock should trade near the deal price minus a risk spread. Consider merger arbitrage if the spread is attractive relative to the timeline and regulatory risk.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$72.15
T+0 close · Aug 10, 2026 · via day close
Latest settled
+0.80%
T+60 · $72.73
Vs SPY
+1.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $72.15entry
  2. T+1 · 3mo ago +0.11%α −0.14% · $72.23
  3. T+5 · 3mo ago +0.10%α +0.50% · $72.22
  4. T+20 · 2mo ago +0.14%α +1.20% · $72.25
  5. T+60 · 12d ago +0.80%α +1.29% · $72.73
Loading chart...

Executive Summary

Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to vote on its acquisition by Merck KGaA (Parent) for $73.00 per share in cash, a 24% premium over the $58.88 closing price on June 24, 2026. The all-cash deal values Bio-Techne at an implied total enterprise value of approximately $11.3 billion. The Board unanimously recommends approval, and Goldman Sachs rendered a fairness opinion. The merger is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals, with no financing condition for Parent.

Key Financial Metrics

Deal Value
$11.6B
Premium
24%
Deal Type
merger

Key Facts

  • Bio-Techne to be acquired by Merck KGaA for $73.00 per share in cash.
  • Merger consideration represents a 24% premium over the $58.88 closing price on June 24, 2026.
  • Implied total enterprise value of approximately $11.3 billion.
  • Board unanimously recommends shareholders vote FOR the merger.
  • Goldman Sachs rendered a fairness opinion that the $73.00 per share is fair from a financial point of view.
  • No financing condition; Parent has represented it has sufficient funds on hand.
  • HSR Act notifications filed on July 16, 2026; deal expected to close late 2026 or early 2027.
  • Bio-Techne termination fee of $230,455,000; Parent termination fee of $576,140,000.

Financial Impact

All-cash acquisition at $73.00 per share, implying an enterprise value of approximately $11.3 billion, representing a 24% premium to the undisturbed stock price.

revenueepsdebtdilution

Risk Factors

  • Regulatory approvals (HSR, foreign antitrust/investment screening) may impose conditions or cause delays.
  • Shareholder vote required; failure to obtain approval would terminate the deal.
  • A 'Burdensome Condition' from regulators could allow Parent to walk away.
  • Potential for competing superior proposal, though deal protections (termination fee, no-shop) are in place.
  • If the deal fails, TECH stock could decline significantly from current levels.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
41% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
PREM14A Filing (Primary)0001140361-26-032037
Document: ny20078105x1_ex107.htm0001140361-26-032037
Document: 0001140361-26-032037-index-headers.html0001140361-26-032037
Document: 0001140361-26-032037-index.html0001140361-26-032037
Document: 0001140361-26-032037.txt0001140361-26-032037

Track record

12 reports on TECH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +2.07% at T+60 after the Jun 25, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 10-Q/A Neutral 1/10 Entry $72.80 Now $72.79 −0.01% settles Dec 14
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $72.66 Now $72.79 +0.18% settles Dec 4
  3. Nov 3, 202612d ago 8-K Neutral 2/10 Entry $72.73 Now $72.79 +0.08% settles Dec 3
  4. Nov 3, 202612d ago Press Release Neutral 2/10 Entry $72.73 Now $72.79 +0.08% settles Dec 3
  5. Oct 29, 202618d ago Institutional Cluster Bearish 4/10 Entry $72.71 Now $72.79 −0.11% settles Nov 27
  6. Oct 28, 202619d ago 10-K/A Neutral 3/10 Entry $72.71 Now $72.79 +0.11% settles Nov 27
  7. Sep 23, 20267w ago 8-K Bullish 6/10 Entry $72.57 to $72.62 Now $72.79 +0.30% ▲ +0.07% +0.49% vs SPY
  8. Sep 23, 20267w ago Press Release Bullish 6/10 Entry $72.52 to $72.64 Now $72.79 +0.37% ▲ +0.17% −0.52% vs SPY
  9. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  10. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $72.23 to $72.08 Now $72.79 +0.78% ▼ −0.21% +1.69% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026